BioSpace News Archive

Myrtelle Inc. and rAAVen Therapeutics today announced a partnership to develop novel recombinant adeno-associated virus (“rAAV”) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.

InvisiShield Technologies Ltd. today announced its Scientific Advisory Board (SAB) which is comprised of four experts in immunology and virology, including two Nobel Laureates.

Cyclo Therapeutics, Inc. today provided updates for the Company’s Trappsol® Cyclo™ clinical program and provided a summary of key achievements in 2022, focused on our clinical portfolio of two neurodegenerative diseases with major unmet medical needs.

PAVmed Inc. and its majority-owned subsidiaries Lucid Diagnostics Inc. and Veris Health Inc. today announced they will hold a joint conference call to provide a strategic business update on Tuesday, January 17, 2023 at 4:30PM EDT.

Avinger, Inc. today announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration for Pantheris LV.

Zynerba Pharmaceuticals, Inc. today announces the publication of a paper entitled, “Role of the Endocannabinoid System in Fragile X Syndrome: Potential Mechanisms for Benefit From Cannabidiol Treatment,” in the Journal of Neurodevelopmental Disorders. The review of evidence suggests a central role for the endocannabinoid sys

Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA) today announced the Company’s subsidiary Jiangsu Huadong Medical Device Industrial Co., Ltd (“Jiangsu Huadong”) has entered into a strategic cooperation agreement (the “Cooperation Agreement”) with Getein Biotech Inc.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that it has elected to redeem on March 17, 2023 (the “Redemption Date”) all of its outstanding 1.25% convertible senior notes due 2024 (the “Notes”) pursuant to Section 4.03 of the Indenture, dated as of November 18, 2019.

Citius Pharmaceuticals, Inc. today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.

XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations.